{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1539","upperLimit":"0.2605","value":"0.2072"},{"groupId":"OG001","lowerLimit":"0.3044","upperLimit":"0.4301","value":"0.3673"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"226"}],"units":"Participants"}],"description":"Grade 3 or 4 nausea, diarrhea, dehydration, radiation dermatitis, mucositis due to radiation. Severe and undesirable adverse event is considered as grade 3; Life-threatening or disabling adverse event is grade 4. Grade 4 is worse than grade 3.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40;dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.","id":"OG000","title":"Vincristine, Dactinomycin, Cyclophosphamide (VAC)"},{"description":"Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13,16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.","id":"OG001","title":"VAC Alternating With Vincristine, Irinotecan (VI)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 15 weeks","title":"Incidence of Toxicity","type":"SECONDARY","unitOfMeasure":"Probability"}